Patents Issued in December 28, 2017
-
Publication number: 20170369498Abstract: Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.Type: ApplicationFiled: July 7, 2017Publication date: December 28, 2017Applicants: Merck Sharp & Dohme Corp., LAWRENCE LIVERMORE NATIONAL SECURITY, LLCInventors: Daniel Bensen, Zhiyong Chen, John Finn, Thanh T. Lam, Suk J. Lee, Xiaoming Li, Douglas W. Phillipson, Leslie W. Tari, Michael Trzoss, Junhu Zhang, Felice C. Lightstone, Toan B. Nguyen, Sergio E. Wong, Paul Aristoff, Michael Jung
-
Publication number: 20170369499Abstract: Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, XY, RY1 RY2 and RY3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.Type: ApplicationFiled: September 8, 2017Publication date: December 28, 2017Inventors: Roushan AFROZE, Indu T. BHARATHAN, Jeffrey P. CIAVARRI, Paul E. FLEMING, Jeffrey L. GAULIN, Mario GIRARD, Steven P. LANGSTON, Francois SOUCY, Tzu-Tshin WONG, Yingchun YE
-
Publication number: 20170369500Abstract: The present invention provides conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compounds and pharmaceutical compositions comprising these compounds. Preferably, the compounds exhibit dual inhibition of microtubule assembly and receptor tyrosine kinases. Methods of treating cancer comprising administering a therapeutically effective amount of at least one conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compound to a patient is disclosed.Type: ApplicationFiled: December 16, 2015Publication date: December 28, 2017Applicant: DUQUESNE UNIVERSITY OF THE HOLY SPIRITInventor: ALEEM GANGJEE
-
Publication number: 20170369501Abstract: The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them, wherein A1, A2, A3, A4, A5, A6, Y, R2 and R7 are as defined herein, and methods for producing such compounds.Type: ApplicationFiled: March 14, 2016Publication date: December 28, 2017Applicant: 4SC AGInventors: Stefan TASLER, Ilga KRIMMELBEIN
-
Publication number: 20170369502Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: August 16, 2017Publication date: December 28, 2017Inventors: John O. Link, Jeromy J. Cottell, Teresa Alejandra Trejo Martin, Elizabeth M. Bacon
-
Publication number: 20170369503Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.Type: ApplicationFiled: February 6, 2017Publication date: December 28, 2017Applicant: LIXTE BIOTECHNOLOGY, INC.Inventors: John S KOVACH, Francis JOHNSON
-
Publication number: 20170369504Abstract: The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.Type: ApplicationFiled: December 30, 2015Publication date: December 28, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Jong Ouk BAEK, Jae Hyuk JUNG, Ho Seok KIM, Tae Hee HA, Kwee Hyun SUH
-
Publication number: 20170369505Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3, 2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: June 22, 2017Publication date: December 28, 2017Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Sean Bollinger, James C. Tarr, Paul Spearing, Julie L. Engers, Madeline Long, Thomas M. Bridges
-
Publication number: 20170369506Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: ApplicationFiled: August 16, 2017Publication date: December 28, 2017Applicant: Pfizer Inc.Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill
-
Publication number: 20170369507Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.Type: ApplicationFiled: December 1, 2015Publication date: December 28, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Fischer Christian, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Michael J. Ellis, Sara Esposite, Qingmei Hong, Chunhui Huang, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Ryan D. Otte, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Patrick Pengcheng Shao, David L. Sloman, Feroze Ujjainwalla, Catherine White, Zhicai Wu, Yang Yu, Kake Zhao, Craig R. Gibeau
-
Publication number: 20170369508Abstract: A compound having the following formula: which can also be embedded into a conjugated oligomeric of polymeric backbone, is proposed for optical and electro optical applications.Type: ApplicationFiled: June 27, 2016Publication date: December 28, 2017Applicant: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)Inventor: Giuseppe SFORAZZINI
-
Publication number: 20170369509Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.Type: ApplicationFiled: September 7, 2017Publication date: December 28, 2017Applicants: Shionogi & Co., Ltd., ViiV Healthcare CompanyInventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
-
Publication number: 20170369510Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.Type: ApplicationFiled: September 8, 2017Publication date: December 28, 2017Applicant: Genentech, Inc.Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
-
Publication number: 20170369511Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.Type: ApplicationFiled: June 13, 2017Publication date: December 28, 2017Inventors: Alfredo C. CASTRO, Catherine A. EVANS, Martin R. TREMBLAY
-
Publication number: 20170369512Abstract: A process for a continuous production of a boronic acid derivative based on a Matteson boronic ester homologation and an apparatus of performing the process are disclosed.Type: ApplicationFiled: December 9, 2015Publication date: December 28, 2017Inventors: Ulfried Felfer, Clemens Stueckler, Stefan Steinhofer, Andreas Pelz, Marcus Hanacek, Thomas Heinrich Pabst, George Winkler, Peter Poechlauer, Bas Ritzen, Michel Goldbach
-
Publication number: 20170369513Abstract: An object of the present invention is to provide a silicon oligomer having a novel function that has not been achieved by a conventional condensation product of water and a tetraalkoxysilane. Provided are a silicon oligomer represented by the following formula (I) and a production method therefor: wherein R1 to R10 each independently is an alkyl group or a hydroxyalkyl group, each having 1 to 4 carbon atoms; X1 to X3 each independently is a group represented by the following formula (II); n is 0 or 1; and m is an integer of 1 to 3 when n is 0, and m is 1 when n is 1: wherein A is an alkylene group having 2 to 4 carbon atoms which may be branched, and 1 is an integer of 1 to 3.Type: ApplicationFiled: September 8, 2017Publication date: December 28, 2017Applicant: JCU CORPORATIONInventors: Daisuke Sadohara, Kenichi Nishikawa, Yasutake Nemichi, Hisayuki Toda, Hiroki Yasuda, Shinsuke Takagi, Christopher Ernest John Cordonier
-
Publication number: 20170369514Abstract: A method for producing an organohalosilane, the method comprising: reacting an organic compound comprising a halogen-substituted or unsubstituted aromatic compound with a hydridohalosilane mixture comprising at least two different hydridohalosilanes of formula (I) RnSiHmX4-m-n, where each R is independently C1-C14 hydrocarbyl or C1-C14 hologen-substituted hydrocarbyl, X is fluoro, chloro, bromo, or iodo, n is 0, 1, or 2, m is 1, 2, or 3 and m+n is 1, 2, or 3, in the presence of a catalyst comprising one or more of the elements Sc, Y, Ti, Zr, Hf, Nb, B, Al, Ga, In, C, Si, Ge, Sn, or Pb, at a temperature greater than 100° C.Type: ApplicationFiled: February 3, 2016Publication date: December 28, 2017Inventor: John Michael Gohndrone
-
Publication number: 20170369515Abstract: The present disclosure relates to a ligand compound, a catalyst system for oligomerization, and a method for olefin oligomerization using the same. The catalyst system for oligomerization using the ligand compound according to the present disclosure has excellent catalytic activity, exhibits high selectivity to 1-hexene and 1-octene, and greatly reduces the production of the by-products, thereby enabling efficient preparation of alpha-olefin.Type: ApplicationFiled: January 26, 2016Publication date: December 28, 2017Inventors: Eun Ji SHIN, Yong Ho LEE, Jin Young PARK, Seok Pil SA, Ki Soo LEE, Seul Ki IM
-
Publication number: 20170369516Abstract: The present invention is directed to oxidized lipids and pharmaceutical compositions comprising the same. The present invention is also directed to methods of making an oxidized lipid of the invention and to methods of treating or preventing fibrosis or inflammatory diseases or disorders comprising an oxidized lipid of the invention.Type: ApplicationFiled: August 16, 2017Publication date: December 28, 2017Inventors: Eti Kovalevski ISHAI, Itzhak MENDEL, Yaniv SALEM, Niva YACOV, Eyal BREITBART
-
Publication number: 20170369517Abstract: Embodiments of the present invention report compositions, systems and methods for obtaining xylo-oligosaccharide-rich extracts from agricultural by-product streams. In certain embodiments, compositions and methods are directed to producing xylo-oligosaccharide-rich extracts with increased amounts and/or concentrations of degrees of polymerization (DP) of 3 or greater (DP3+). In other embodiments, compositions and methods relate to the production of products containing high soluble fiber, for example, xylo-oligosaccharides of DP3 or greater, from oat hull by-products. In yet other embodiments, xylo-oligosaccharides-rich extracts derived from oat hulls can be further processed to generate useful liquids for example, liquids containing soluble solids and powdered sweeteners and other useful consumer products.Type: ApplicationFiled: December 9, 2015Publication date: December 28, 2017Inventors: Joseph Shekiro, III, Nate Lukecart, Christopher John Scarlata, Richard T. Elander, Bernhard Van Lengerich, David Templeton
-
Publication number: 20170369518Abstract: The present invention relates to a method for the chlorination of a sucrose-6-acylate to produce a 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acylate wherein said method includes steps of: (i) combining the sucrose-6-acylate with a chlorinating agent in a reaction vehicle comprising a tertiary amide to afford a mixture; (ii) heating said mixture for a heating period in order to provide chlorination of sucrose-6-acylate at the 4, 1? and 6? positions thereof; and (iii) quenching the product stream of (ii) to produce a 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acylate; wherein before said quenching, a portion of said tertiary amide is removed by extraction into a solvent in which said tertiary amide is at least partially soluble.Type: ApplicationFiled: June 20, 2017Publication date: December 28, 2017Applicant: Tate & Lyle Technology LimitedInventors: David DENTEL, Thomas EILERS, Edward MICINSKI
-
Publication number: 20170369519Abstract: The present invention relates to a method for the stereoselective preparation of apiose derivatives from allylic alcohol compounds and allene compounds using catalytic asymmetric synthesis. The method for the stereoselective preparation of apiose derivatives of the present invention is based on the catalytic asymmetric synthesis from allylic alcohol compounds and allene compounds in the presence of a metal catalyst, so that apiose derivatives can be produced stereoselectively, with high yield, with high optical purity regardless of the types of substituents of the compounds. The method of the invention can also be used for the preparation of oligosaccharides including monosaccharides, disaccharides, and polysaccharides or various compounds including apiose derivatives because the method can minimize the production of by-products without using an activating group, unlike the conventional method for the preparation of adipose derivatives.Type: ApplicationFiled: April 17, 2017Publication date: December 28, 2017Inventors: Young Ho RHEE, Mijin KIM, Soyeong KANG
-
Publication number: 20170369520Abstract: The present invention relates to application of N(6)-(2-hydroxyethyl)-adenosine (HEA) and its derivatives as an adenosine A1 receptor agonist in preparation of drug or food, the HEA and its derivatives are used in treatment of diseases relating to adenosine receptor regulator, such as insomnia, pain, convulsion, apoplexia, Parkinson's disease, opioid drug addiction and kidney ischemia reperfusion injury etc. The present invention provides a new method for treatment of the diseases relating to nervous system and kidney.Type: ApplicationFiled: September 11, 2017Publication date: December 28, 2017Inventors: Yiqiu Chai, Bichun Zhu, Xiuxiu Peng, Yiwei Jin
-
Publication number: 20170369521Abstract: The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3, 15a, 16a, 1713-tetraol (estetr-01), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10), 16-tetraene, wherein A is a protecting group and B is —Si(R2)3. The invention further relates to a process for the synthesis of 3-A-oxy-estra-1,3,5(10), 15-tetraen-17-one, in which A is a protecting group, via silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, and B is —Si(R2)3.Type: ApplicationFiled: February 7, 2017Publication date: December 28, 2017Applicant: Donesta Bioscience B.V.Inventors: Johannes Jan PLATTEEUW, Herman Jan Tijmen COELINGH BENNINK, Franciscus Wilhelmus Petrus DAMEN, Michiel Christian Alexander VAN VLIET
-
Publication number: 20170369522Abstract: The invention relates to 3?-ethynyl, 3?-hydroxy, 5?-pregnan-20-oxime or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-5 aminobutyric acid receptor-chloride ionophore (GABAA-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.Type: ApplicationFiled: January 11, 2016Publication date: December 28, 2017Applicant: Umecrine Cognition ABInventors: Torbjörn Bäckström, Gianna Ragagnin
-
Publication number: 20170369523Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 8 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Gly or Pro or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have agonizing or antagonizing activity against urotensin II or show inhibition of the STAT6/NCoA-1 interaction and can be used for preventing or treating diseases or disorders related to urotensin II, STAT6 and NCoA-1. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: September 11, 2017Publication date: December 28, 2017Applicant: POLYPHOR AGInventors: John Anthony ROBINSON, Kerstin MÖHLE, Markus SEITZ, Ludovic T. MAILLARD, Roba MOUNME, Frank Otto GOMBERT, Odile SELLIER-KESSLER, Heiko HENZE, Daniel OBRECHT, Christian BISANG, Alexander LEDERER
-
Publication number: 20170369524Abstract: An improvement in of deprotection in solid phase peptide synthesis is disclosed. The method includes the steps of adding the deprotection composition in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated amino acid from the preceding coupling cycle; and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle; and with the coupling solution at a temperature of at least 30° C.Type: ApplicationFiled: April 18, 2017Publication date: December 28, 2017Applicant: CEM CorporationInventor: Jonathan M. Collins
-
Publication number: 20170369525Abstract: A method for specific linkage to a glycoprotein includes obtaining a glycoprotein having a monoglycan or diglycan attached thereto; producing a reactive functional group on a sugar unit on the glycoprotein; and coupling a linker or a payload to the reactive functional group on the glycoprotein.Type: ApplicationFiled: December 31, 2015Publication date: December 28, 2017Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Chao-Pin Lee, Cheng-Chou Yu, Chi-Huey Wong, Chuan-Lung Hsu, Chun-Chung Lee, Shih-Hsien Chuang, Ta-Tung Yuan, Yi-Jen Chen, Yu-Chin Nieh
-
Publication number: 20170369526Abstract: Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.Type: ApplicationFiled: December 11, 2015Publication date: December 28, 2017Applicant: Rensselaer Polytechnic InstituteInventors: Timothy Paul Cleland, Deepak Vashishth
-
Publication number: 20170369527Abstract: The invention relates to a method of immunoaffinity purification which comprises the use of a binding agent which binds to an epitope that it is present at least twice on the target molecule. In another embodiment the method uses at least two different binding agents, each binding to different epitopes on the target molecule.Type: ApplicationFiled: June 7, 2017Publication date: December 28, 2017Inventors: Wilhelmus Josephus Johanna HERMANS, Mark Ronald TEN HAAFT, Anja OVERWEEL
-
Publication number: 20170369528Abstract: Aspects of the present application relates to co-crystal of carfilzomib with maleic acid, process for the preparation of co-crystal of carfilzomib with maleic acid, process for the preparation of pure carfilzomib from co-crystal of carfilzomib with maleic acid and process for the preparation of amorphous carfilzomib.Type: ApplicationFiled: December 31, 2015Publication date: December 28, 2017Inventors: Ramesh Kumar NADGOUD, Sridhar VASAM, Siva Reddy MAKIREDDY, Veerender MURKI, Rakesh GANORKAR, Jithin JOSE, Subba Reddy PEDDI REDDY, Praveen CHAPPA
-
Publication number: 20170369529Abstract: Provided herein are cell penetrating peptides optionally including a cargo moiety linked thereto.Type: ApplicationFiled: December 18, 2015Publication date: December 28, 2017Inventor: Francesca Milletti
-
Publication number: 20170369530Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: August 9, 2017Publication date: December 28, 2017Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
-
Publication number: 20170369531Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2?,6?-dimethyltyrosine (Dmt) residue in place of the N-terminal tyrosine residue a position 1. These peptide analogs exhibit increased solubility compared to similar tetrapeptide analogs while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: March 6, 2017Publication date: December 28, 2017Applicants: The Administrators of the Tulane Educational Fund, Department of Veterans Affairs (US)Inventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20170369532Abstract: This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.Type: ApplicationFiled: January 22, 2016Publication date: December 28, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Andrea CARFI, Claudio CIFERRI, Yi XING
-
Publication number: 20170369533Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.Type: ApplicationFiled: July 26, 2017Publication date: December 28, 2017Inventors: Vincent C. Bond, Michael POWELL, Ming Bo HUANG, Syed ALI
-
Publication number: 20170369534Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.Type: ApplicationFiled: September 12, 2017Publication date: December 28, 2017Inventors: Evelien M. BUNNIK, Jerome Hubertina Henricus Victor CUSTERS, Gerrit C. SCHEPER, Koen OOSTERHUIS, Taco Gilles UIL, Selina KHAN
-
Publication number: 20170369535Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: ApplicationFiled: September 1, 2017Publication date: December 28, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Aaron Vassall, Richard Beers, Jaime Eberle, Wenhai Liu
-
Publication number: 20170369536Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.Type: ApplicationFiled: September 12, 2017Publication date: December 28, 2017Inventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim
-
Publication number: 20170369537Abstract: The present invention relates in general to bacterial cells having a genetic alteration that results in increased expression of a protein of interest and methods of making and using such cells. Aspects of the present invention include Grampositive microorganisms, such as members of the Bacillus genus having a genetic alteration that delays, reduces, or blocks the expression or activation of genes for sporulation, thereby resulting in enhanced expression of a protein of interest. The genetic alteration is one that reduces expression of a kinA gene, a phrA gene or a phrE gene.Type: ApplicationFiled: December 11, 2015Publication date: December 28, 2017Applicant: DANISCO US INC.Inventors: Cristina BONGIORNI, Robert I. CHRISTENSEN, Brian F. SCHMIDT, Anita VAN KIMMENADE
-
Publication number: 20170369538Abstract: DIG-305 insecticidal protein toxins, polynucleotides encoding such toxins, and transgenic plants that produce such toxins are disclosed. Also disclosed are methods for using such toxins to control insect pests in plants, especial crop plants. Methods for preparing transgenic plants expressing the protein toxins and methods for detecting the claimed toxins and polynucleotides in transgenic plants are disclosed.Type: ApplicationFiled: December 16, 2015Publication date: December 28, 2017Applicant: Dow Agrosciences LLCInventors: Timothy D. HEY, Megan L. F. FREY, Xiaoping XU, Audrey Jane ETTER, Elizabeth CALDWELL, Ted LETHERER, Navin ELANGO, Kenneth NARVA
-
Publication number: 20170369539Abstract: The subject invention concerns Bacillus thuringiensis modified Cry1Ca insecticidal toxins and the polynucleotide sequences which encode these toxins. Uses in transgenic plants are described as are methods for protecting crops from insect pest damage.Type: ApplicationFiled: December 16, 2015Publication date: December 28, 2017Applicant: Dow Agrosciences LLCInventors: Joel J. SHEETS, Kenneth NARVA, Thomas MEADE, Timothy D. HEY, Sek Yee TAN, Audrey Jane ETTER, Todd P. GLANCY, Janna Mai ARMSTRONG, Tristan E. CORAM, Krishna M. MADDURI, James E. KING, Ryan M. LEE, Gaofeng LIN, Jianquan LI
-
Publication number: 20170369540Abstract: The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of modulated plant size, vegetative growth, organ number, plant architecture, sterility or seedling lethality in plants. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having such modulated growth or phenotype characteristics that are altered with respect to wild type plants grown under similar conditions.Type: ApplicationFiled: June 21, 2017Publication date: December 28, 2017Inventors: Maxim Troukhan, Peter Mascia
-
Publication number: 20170369541Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.Type: ApplicationFiled: January 3, 2017Publication date: December 28, 2017Applicant: Genzyme CorporationInventors: Catherine R. O'Riordan, William H. Brondyk
-
Publication number: 20170369542Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: July 7, 2017Publication date: December 28, 2017Applicant: PIERIS PHARMACEUTICALS GMBHInventors: Stefan TRENTMANN, Gabriele MATSCHINER, Arne SKERRA, Andreas HOHLBAUM, Martin HUELSMEYER, Hendrik GILLE, Hans-Juergen CHRISTIAN, Kristian JENSEN, Rachida Siham BEL AIBA
-
Publication number: 20170369543Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.Type: ApplicationFiled: July 17, 2017Publication date: December 28, 2017Applicant: University of Iowa Research FoundationInventor: Gregory S. Hageman
-
Publication number: 20170369544Abstract: A fluid sample container comprising a protease, when a sample fluid is placed in the fluid sample container the protease breaking a target analyte in the sample fluid into at least two peptides, the at least two peptides being smaller than the original target analyte.Type: ApplicationFiled: December 23, 2015Publication date: December 28, 2017Applicant: Siemens Healthcare Diagnostics Inc.Inventors: David Ledden, Eric Cowden
-
Publication number: 20170369545Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.Type: ApplicationFiled: January 21, 2016Publication date: December 28, 2017Inventors: Jerome VICOGNE, Oleg MELNYK, Nathalie OLLIVIER, Eric ADRIAENSSENS, Berenice LECLERCQ, Claire SIMONNEAU, Giovanni DE NOLA, Ermanno GHERARDI, Hugo DE JONGE
-
Publication number: 20170369546Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.Type: ApplicationFiled: August 30, 2017Publication date: December 28, 2017Applicant: LifeNet HealthInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20170369547Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: ApplicationFiled: March 27, 2017Publication date: December 28, 2017Inventor: George N. Cox